Related Experiment Video
Updated: Oct 5, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
COVID-19 and Preeclampsia: Overlapping Features in Pregnancy
Ramasamy Sathiya1, Jayanthi Rajendran1, Saravanan Sumathi1
1Department of Biochemistry, Mahatma Gandhi Medical College & Research Institute, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry, India.
Insights
COVID-19 and preeclampsia share symptoms, potentially leading to misdiagnosis in pregnant women. Angiogenic markers like sFlt-1/PlGF can help differentiate a COVID-19-induced preeclampsia-like syndrome from actual preeclampsia.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Cardiovascular Medicine
Background:
- Preeclampsia is a hypertensive disorder affecting 8-10% of pregnant women in India.
- COVID-19, caused by SARS-CoV-2, presents unique challenges in pregnancy.
- Coincidental symptoms between COVID-19 and preeclampsia can lead to diagnostic difficulties.
Purpose of the Study:
- To explore the diagnostic challenges in pregnant women with overlapping symptoms of COVID-19 and preeclampsia.
- To highlight the potential for a COVID-19-induced preeclampsia-like syndrome.
- To emphasize the role of angiogenic markers in differential diagnosis.
Main Methods:
- Review of clinical features and potential pathophysiological links between SARS-CoV-2 infection and preeclampsia.
- Comparison of shared symptoms: hypertension, proteinuria, thrombocytopenia, elevated liver enzymes, and pro-inflammatory cytokines.
- Evaluation of angiogenic markers (sEng, PAPP-A, sFlt-1, PlGF) for differentiating conditions.
Main Results:
- SARS-CoV-2 infection and preeclampsia share several clinical and laboratory features, complicating diagnosis.
- A preeclampsia-like syndrome may arise in pregnant women with COVID-19 due to mechanisms like RAS disturbance and endothelial dysfunction.
- Elevated sFlt-1 and reduced PlGF levels, indicated by the sFlt-1/PlGF ratio, are crucial for early preeclampsia diagnosis and may help differentiate from COVID-19 effects.
Conclusions:
- Differential diagnosis between COVID-19 and preeclampsia in pregnant women is challenging due to overlapping symptoms.
- Angiogenic markers, particularly the sFlt-1/PlGF ratio, are vital for distinguishing preeclampsia from COVID-19-related hypertensive disorders.
- Accurate differentiation using angiogenic markers can prevent unnecessary interventions and preterm labor.
Abstract:
Coronavirus disease 2019 (COVID-19) is a global respiratory disease with unique features that have placed all medical professionals in an alarming situation. Preeclampsia is a hypertensive disorder of pregnancy affecting 8%-10% of India's pregnant population. Assuming that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells through the angiotensin-converting enzyme 2 (ACE2) receptor, the resulting symptoms are due to vasoconstriction, caused by disturbances in the renin-angiotensin system (RAS). Other features of preeclampsia include endothelial dysfunction due to placental ischemia, leading to imbalances in angiogenic and antiangiogenic factors which result in increased blood pressure, proteinuria, altered hepatic enzymes, renal failure, and thrombocytopenia, amongst others. The increased prevalence of preeclampsia that was seen among mothers with SARS-CoV-2 infection might be due to misdiagnosis, as COVID-19 and preeclampsia have coincidental medical features. The major similarities of SARS-CoV-2-infected and preeclamptic women are a rise in pro-inflammatory cytokines, and increased serum ferritin and thrombocytopenia. Therefore, differential diagnosis might be difficult in pregnant women with COVID-19 who present with hypertension and proteinuria, thrombocytopenia, or elevated liver enzymes. The most promising markers for earlier diagnosis of preeclampsia is soluble endoglin (sEng), pregnancy-associated plasma protein-A (PAPP-A), soluble fms-like tyrosine kinase 1 (sFlt-1), and placental growth factor (PlGF). Due to placental hypoxia, sFlt-1 will be overproduced, thus inhibiting PlGF, and this alteration will be observed in the circulation five weeks or more before the onset of symptoms. The sFlt-1/PlGF ratio may also be modified via infectious states, but unregulated levels of those mediators are related to placental insufficiency. Hence, pregnant women with COVID-19 may develop a preeclampsia-like syndrome that might be differentiated properly by angiogenic markers to avoid unnecessary interventions and induced preterm labor.
More Related Videos
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Related Concept Videos
Mitral Valve Prolapse III: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hormonal Regulation
Diabetes Mellitus: Type 2 and Gestational
Hypertension II: Pathophysiology
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...